UNSPSC 51434304: Piretanide sodium

This classification denotes a loop diuretic C17H17N2O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4757J7S0V0, chemically known as benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-, sodium salt (1:1), but more generally known as piretanide sodium, which bears US NIH Compound Identifier 73425479. European Medicines Agency schedules Piretanide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03870MIG.

Most nations, for tariff and trade purposes, schedule piretanide sodium under HS 29350090 and SITC 51580. As of Q4 2014, PIRETANIDE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)OC2C(CC(CC2S(=O)(=O)N)C(=O)[O-])N3CCCC3.[NA+].

UNSPSC 51434304 Piretanide sodium is a Commodity code representing a single pharmaceutical product line purchased by state and local public health and human services agencies primarily through emergency medical services, pharmacy benefit programs, and multi-state cooperative purchasing arrangements. State and local governments buy piretanide sodium and related diuretic medications as components of advanced life support pharmaceutical inventories, generic pharmaceutical procurement contracts for public healthcare systems, and direct-to-manufacturer pharmacy initiatives designed to improve prescription fulfillment and cost management. Issuing bodies include city fire rescue departments (such as Tampa Fire Rescue), state health and human services commissions, and multi-state cooperative purchasing alliances that aggregate demand across participating state and local healthcare facilities. The code sees activity from municipal purchasing departments procuring for emergency medical services, state-level pharmacy benefit administrators, and regional cooperative purchasing organizations serving multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for advanced life support medications including piretanide-related compounds, with a due date of April 8, 2026 and an estimated contract value of $40,000.00; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer pharmacy initiative; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Tampa and MMCAP opportunities reflect active procurement for emergency medical services and state healthcare system inventory; the Texas RFI signals emerging demand for alternative pharmaceutical distribution models that may reshape future direct-sourcing opportunities for commodity pharmaceutical products.